Skip to main content
Erschienen in: Urolithiasis 2/2016

01.04.2016 | Original Paper

Potassium citrate decreases urine calcium excretion in patients with hypocitraturic calcium oxalate nephrolithiasis

verfasst von: Yan Song, Natalia Hernandez, Jonathan Shoag, David S. Goldfarb, Brian H. Eisner

Erschienen in: Urolithiasis | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Two previous studies (<10 patients each) have demonstrated that alkali therapy may reduce urine calcium excretion in patients with calcium oxalate nephrolithiasis. The hypothesized mechanisms are (1) a decrease in bone turnover due to systemic alkalinization by the medications; (2) binding of calcium by citrate in the gastrointestinal tract; (3) direct effects on TRPV5 activity in the distal tubule. We performed a retrospective review of patients on potassium citrate therapy to evaluate the effects of this medication on urinary calcium excretion. A retrospective review was performed of a metabolic stone database at a tertiary care academic hospital. Patients were identified with a history of calcium oxalate nephrolithiasis and hypocitraturia who were on potassium citrate therapy for a minimum of 3 months. 24-h urine composition was assessed prior to the initiation of potassium citrate therapy and after 3 months of therapy. Patients received 30–60 mEq potassium citrate by mouth daily. Inclusion criterion was a change in urine potassium of 20 mEq/day or greater, which suggests compliance with potassium citrate therapy. Paired t test was used to compare therapeutic effect. Twenty-two patients were evaluated. Mean age was 58.8 years (SD 14.0), mean BMI was 29.6 kg/m2 (SD 5.9), and gender prevalence was 36.4 % female:63.6 % male. Mean pre-treatment 24-h urine values were as follows: citrate 280.0 mg/day, potassium 58.7 mEq/day, calcium 216.0 mg/day, pH 5.87. Potassium citrate therapy was associated with statistically significant changes in each of these parameters—citrate increased to 548.4 mg/day (p < 0.0001), potassium increased to 94.1 mEq/day (p < 0.0001), calcium decreased to 156.5 mg/day (p = 0.04), pH increased to 6.47 (p = 0.001). Urine sodium excretion was not different pre- and post-therapy (175 mEq/day pre-therapy versus 201 mEq/day post-therapy, p = NS). Urinary calcium excretion decreased by a mean of 60 mg/day on potassium citrate therapy—a nearly 30 % decrease in urine calcium excretion. These data lend support to the hypothesis that alkali therapy reduces urine calcium excretion.
Literatur
1.
Zurück zum Zitat Scales CD Jr, Smith AC, Hanley JM, Saigal CS (2012) Urologic diseases in America project. Prevalence of kidney stones in the United States. Eur Urol 62:160–165CrossRefPubMedPubMedCentral Scales CD Jr, Smith AC, Hanley JM, Saigal CS (2012) Urologic diseases in America project. Prevalence of kidney stones in the United States. Eur Urol 62:160–165CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Saigal CS, Joyce G, Timilsina AR (2005) Urologic diseases in America project. Direct and indirect costs of nephrolithiasis in an employed population: opportunity for disease management? Kidney Int 68:1808–1814CrossRefPubMed Saigal CS, Joyce G, Timilsina AR (2005) Urologic diseases in America project. Direct and indirect costs of nephrolithiasis in an employed population: opportunity for disease management? Kidney Int 68:1808–1814CrossRefPubMed
3.
Zurück zum Zitat Rule AD, Lieske JC, Li X, Melton LJ 3rd, Krambeck AE, Bergstralh EJ (2014) The ROKS nomogram for predicting a second symptomatic stone episode. J Am Soc Nephrol 25:2878–2886CrossRefPubMedPubMedCentral Rule AD, Lieske JC, Li X, Melton LJ 3rd, Krambeck AE, Bergstralh EJ (2014) The ROKS nomogram for predicting a second symptomatic stone episode. J Am Soc Nephrol 25:2878–2886CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Levy FL, Adams-Huet B, Pak CY (1995) Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocol. Am J Med 98:50–59CrossRefPubMed Levy FL, Adams-Huet B, Pak CY (1995) Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocol. Am J Med 98:50–59CrossRefPubMed
5.
Zurück zum Zitat Eisner BH, Sheth S, Dretler SP, Herrick B, Pais VM Jr (2012) Abnormalities of 24-hour urine composition in first-time and recurrent stone-formers. Urology 80:776–779CrossRefPubMed Eisner BH, Sheth S, Dretler SP, Herrick B, Pais VM Jr (2012) Abnormalities of 24-hour urine composition in first-time and recurrent stone-formers. Urology 80:776–779CrossRefPubMed
6.
Zurück zum Zitat Ettinger B, Pak CY, Citron JT, Thomas C, Adams-Huet B, Vangessel A (1997) Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 158:2069–2073CrossRefPubMed Ettinger B, Pak CY, Citron JT, Thomas C, Adams-Huet B, Vangessel A (1997) Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 158:2069–2073CrossRefPubMed
7.
Zurück zum Zitat Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CY (1993) Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol 150:1761–1764PubMed Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CY (1993) Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol 150:1761–1764PubMed
8.
Zurück zum Zitat Hamm LL, Hering-Smith KS (2002) Pathophysiology of hypocitraturic nephrolithiasis. Endocrinol Metab Clin North Am 31:885–893CrossRefPubMed Hamm LL, Hering-Smith KS (2002) Pathophysiology of hypocitraturic nephrolithiasis. Endocrinol Metab Clin North Am 31:885–893CrossRefPubMed
9.
Zurück zum Zitat Jehle S, Hulter HN, Krapf R (2013) Effect of potassium citrate on bone density, microarchitecture, and fracture risk in healthy older adults without osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 98:207–217CrossRefPubMed Jehle S, Hulter HN, Krapf R (2013) Effect of potassium citrate on bone density, microarchitecture, and fracture risk in healthy older adults without osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 98:207–217CrossRefPubMed
10.
Zurück zum Zitat Nijenhuis T, Renkema KY, Hoenderop JG, Bindels RJ (2006) Acid-base status determines the renal expression of Ca2+ and Mg2+ transport proteins. J Am Soc Nephrol 17:617–626CrossRefPubMed Nijenhuis T, Renkema KY, Hoenderop JG, Bindels RJ (2006) Acid-base status determines the renal expression of Ca2+ and Mg2+ transport proteins. J Am Soc Nephrol 17:617–626CrossRefPubMed
11.
Zurück zum Zitat Moses R, Pais VM Jr, Ursiny M, Prien EL Jr, Miller N, Eisner BH (2015) Changes in stone composition over two decades: evaluation of over 10,000 stone analyses. Urolithiasis 43:135–139CrossRefPubMed Moses R, Pais VM Jr, Ursiny M, Prien EL Jr, Miller N, Eisner BH (2015) Changes in stone composition over two decades: evaluation of over 10,000 stone analyses. Urolithiasis 43:135–139CrossRefPubMed
12.
Zurück zum Zitat Park S, Pearle MS (2007) Pathophysiology and management of calcium stones. Urol Clin North Am 34:323–334CrossRefPubMed Park S, Pearle MS (2007) Pathophysiology and management of calcium stones. Urol Clin North Am 34:323–334CrossRefPubMed
13.
Zurück zum Zitat Fuselier HA, Ward DM, Lindberg JS, Allen JM, Husserl FE, Marcucci PA et al (1995) Urinary Tamm–Horsfall protein increased after potassium citrate therapy in calcium stone formers. Urology 45:942–946CrossRefPubMed Fuselier HA, Ward DM, Lindberg JS, Allen JM, Husserl FE, Marcucci PA et al (1995) Urinary Tamm–Horsfall protein increased after potassium citrate therapy in calcium stone formers. Urology 45:942–946CrossRefPubMed
14.
Zurück zum Zitat Hess B, Zipperle L, Jaeger P (1993) Citrate and calcium effects on Tamm–Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation. Am J Physiol 265:F784–F791PubMed Hess B, Zipperle L, Jaeger P (1993) Citrate and calcium effects on Tamm–Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation. Am J Physiol 265:F784–F791PubMed
15.
Zurück zum Zitat Sakhaee K, Alpern R, Jacobson HR, Pak CY (1991) Contrasting effects of various potassium salts on renal citrate excretion. J Clin Endocrinol Metab 72:396–400CrossRefPubMed Sakhaee K, Alpern R, Jacobson HR, Pak CY (1991) Contrasting effects of various potassium salts on renal citrate excretion. J Clin Endocrinol Metab 72:396–400CrossRefPubMed
16.
Zurück zum Zitat Pak CY, Peterson R (1986) Successful treatment of hyperuricosuric calcium oxalate nephrolithiasis with potassium citrate. Arch Intern Med 146:863–867CrossRefPubMed Pak CY, Peterson R (1986) Successful treatment of hyperuricosuric calcium oxalate nephrolithiasis with potassium citrate. Arch Intern Med 146:863–867CrossRefPubMed
17.
Zurück zum Zitat Pak CY, Fuller C (1986) Idiopathic hypocitraturic calcium-oxalate nephrolithiasis successfully treated with potassium citrate. Ann Intern Med 104:33–37CrossRefPubMed Pak CY, Fuller C (1986) Idiopathic hypocitraturic calcium-oxalate nephrolithiasis successfully treated with potassium citrate. Ann Intern Med 104:33–37CrossRefPubMed
18.
Zurück zum Zitat Robinson MR, Leitao VA, Haleblian GE, Scales CD Jr, Chandrashekar A, Pierre SA et al (2009) Impact of long-term potassium citrate therapy on urinary profiles and recurrent stone formation. J Urol 181:1145–1150CrossRefPubMed Robinson MR, Leitao VA, Haleblian GE, Scales CD Jr, Chandrashekar A, Pierre SA et al (2009) Impact of long-term potassium citrate therapy on urinary profiles and recurrent stone formation. J Urol 181:1145–1150CrossRefPubMed
Metadaten
Titel
Potassium citrate decreases urine calcium excretion in patients with hypocitraturic calcium oxalate nephrolithiasis
verfasst von
Yan Song
Natalia Hernandez
Jonathan Shoag
David S. Goldfarb
Brian H. Eisner
Publikationsdatum
01.04.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Urolithiasis / Ausgabe 2/2016
Print ISSN: 2194-7228
Elektronische ISSN: 2194-7236
DOI
https://doi.org/10.1007/s00240-015-0819-8

Weitere Artikel der Ausgabe 2/2016

Urolithiasis 2/2016 Zur Ausgabe

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.